[1]
Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS, Chronic Kidney Disease Epidemiology Collaboration. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2009 Jul:54(1):33-42. doi: 10.1053/j.ajkd.2009.03.008. Epub 2009 May 17
[PubMed PMID: 19446939]
[2]
Lattanzio F, Corsonello A, Montesanto A, Abbatecola AM, Lofaro D, Passarino G, Fusco S, Corica F, Pedone C, Maggio M, Volpato S, Incalzi RA. Disentangling the Impact of Chronic Kidney Disease, Anemia, and Mobility Limitation on Mortality in Older Patients Discharged From Hospital. The journals of gerontology. Series A, Biological sciences and medical sciences. 2015 Sep:70(9):1120-7. doi: 10.1093/gerona/glv068. Epub 2015 May 19
[PubMed PMID: 25991829]
[3]
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009 May 5:150(9):604-12
[PubMed PMID: 19414839]
[4]
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976:16(1):31-41
[PubMed PMID: 1244564]
[5]
Hundemer GL, White CA, Norman PA, Knoll GA, Tangri N, Sood MM, Hiremath S, Burns KD, McCudden C, Akbari A. Performance of the 2021 Race-Free CKD-EPI Creatinine- and Cystatin C-Based Estimated GFR Equations Among Kidney Transplant Recipients. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2022 Oct:80(4):462-472.e1. doi: 10.1053/j.ajkd.2022.03.014. Epub 2022 May 16
[PubMed PMID: 35588905]
[6]
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS, Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. The New England journal of medicine. 2021 Nov 4:385(19):1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23
[PubMed PMID: 34554658]
[7]
Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2022 Feb:79(2):268-288.e1. doi: 10.1053/j.ajkd.2021.08.003. Epub 2021 Sep 23
[PubMed PMID: 34563581]
[8]
Alahdal AM, Elberry AA. Evaluation of applying drug dose adjustment by physicians in patients with renal impairment. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2012 Jul:20(3):217-20. doi: 10.1016/j.jsps.2011.12.005. Epub 2011 Dec 24
[PubMed PMID: 23960796]
[9]
Salomon L, Deray G, Jaudon MC, Chebassier C, Bossi P, Launay-Vacher V, Diquet B, Ceza JM, Levu S, Brücker G, Ravaud P. Medication misuse in hospitalized patients with renal impairment. International journal for quality in health care : journal of the International Society for Quality in Health Care. 2003 Aug:15(4):331-5
[PubMed PMID: 12930048]
Level 2 (mid-level) evidence
[10]
Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM, CureGN Consortium. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2019 Feb:73(2):218-229. doi: 10.1053/j.ajkd.2018.07.020. Epub 2018 Nov 9
[PubMed PMID: 30420158]
Level 2 (mid-level) evidence
[11]
Paglialunga S, Offman E, Ichhpurani N, Marbury TC, Morimoto BH. Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines. Expert review of clinical pharmacology. 2017 Mar:10(3):273-283. doi: 10.1080/17512433.2017.1274651. Epub 2017 Jan 29
[PubMed PMID: 27998190]
[12]
Zhang L, Xu N, Xiao S, Arya V, Zhao P, Lesko LJ, Huang SM. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. Journal of clinical pharmacology. 2012 Jan:52(1 Suppl):79S-90S. doi: 10.1177/0091270011415410. Epub
[PubMed PMID: 22232757]
Level 3 (low-level) evidence